SHORTWAVE LIFE SCIENCES
PLC
("Shortwave" or "the
Company")
Shortwave Life Science
Announces Strategic Board Addition and Milestone Share
Allocation
Shortwave Life Science Accelerates Growth Strategy with Leadership
Update and Key Milestones
Appointment of Ron Lipsky as Non-Executive
Director
London, 27 November 2024 - Shortwave
Life Sciences (AQSE: PSY), a pioneer in mental health innovation is
pleased to announce the appointment of Ron Lipsky as a
Non-Executive Director with immediate effect.
Ron Chai Lipsky, aged 49, is a
seasoned executive in life sciences and public markets, with an
extensive track record in capital raising, market entry, and value
creation. He brings expertise in overseeing complex regulatory
compliance, fostering investor relations, and delivering strategic
growth for global biotech and pharmaceutical companies. Ron is
recognised for his role in guiding organisations through public
listings, navigating multi-market compliance (ASX, LSE), and
leveraging public market acumen to drive expansion and investor
confidence. He is committed to supporting board-level strategic
direction, performance monitoring, and risk management.
"We are thrilled to welcome Ron
Lipsky to the board as a Non-Executive Director," said Rivki Stern,
Chief Executive Officer of the Company. "Ron brings a wealth of
experience in public markets and a deep understanding of the life
sciences sector, which aligns perfectly with our strategic vision.
His expertise in navigating regulatory landscapes and engaging
investors will be invaluable as we continue to drive growth and
broaden our impact. We look forward to Ron's contribution as we
advance our mission and deliver value to our
stakeholders."
Mr.
Lipsky does not currently hold any ordinary shares in the Company.
The below details all directorships held by the director in any
other company at any time in the previous five years:
|
Current directorships
|
Previous directorships
|
|
|
|
|
Access Ventures Ltd
|
Anubis Pharma
|
|
Cannaccess Ltd
|
|
Except as set out above, there is no
further information regarding Ron Lipsky, that is required to be
disclosed pursuant to Rule 4.9 of the Aquis Growth Market Access
Rulebook.
Allocation of Deferred Guarantee Shares
Pursuant to the Share Purchase
Agreement ("SPA") signed between the Company and Shortwave Pharma
Inc. ("SWP") for the acquisition of 100% of SWP's shares, 7,499,998
Deferred Guarantee Shares were withheld at the time of acquisition.
These shares were held to address any potential warranty claims
arising within 12 months of the transaction's completion. Further
information is found in the announcement of 19 June
2023.
As at November 7, 2024, the first
anniversary of the completion date, no warranty-related claims had
been made by the Company, and no issues requiring utilisation of
the Deferred Guarantee Shares had arisen. Consequently, these
shares will be allocated to the Warrantors as stipulated in the
SPA.
The allocation of the Deferred
Guarantee Shares will proceed with the issue and allotment of
ordinary shares in the Company as follows:
|
Name
|
Number of Deferred Guarantee
Shares
|
|
|
|
|
Roy Kait
|
2,228,055
|
|
Jesse Kaplan
|
246,077
|
|
Nadejda Lisovoder
|
2,162,089
|
|
Rivki Stern Youdkevich
|
2,863,777
|
Following the issue of the Deferred
Guarantee Shares, Rivki Stern, CEO will own 13,662,697 ordinary
shares in the Company, representing 3.61% of the enlarged issued
share capital.
About Shortwave Life Sciences:
Shortwave Life Sciences is a
developer of breakthrough therapies addressing unmet medical needs
in mental health. The Company is committed to the advancement of
innovative solutions through drug development, with a mission to
pioneer breakthrough therapies that transform the landscape of
mental health care. With a team of dedicated experts and a
commitment to innovation, Shortwave Life Sciences is uniquely
positioned to introduce and develop solutions for the complex
challenges of mental health disorders worldwide.
The Directors of the Company accept
responsibility for the contents of this announcement.
For media inquiries, please
contact:
Enquiries:
Company:
Rivki Stern: +972
547621621
Peterhouse Capital Limited:
Corporate Adviser:
+ 44 (0) 20 7469 0930
Corporate Broker:
+44 (0) 20 7220 9797
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Rivki Stern
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Executive Officer
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Shortwave Life Sciences
|
|
b)
|
LEI
|
213800WXCQ1C6GPLHH68
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary shares
of £0.001 value each in Shortwave Life Sciences
Plc
Identification code (ISIN) for
Shortwave Life Sciences plc ordinary shares:
GB00BL6CJQ54
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary
Shares
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
Grant of deferred guarantee ordinary
shares
|
2,863,777
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A
|
|
e)
|
Date of the transaction
|
22 November 2024
|
|
f)
|
Place of the transaction
|
Aquis Growth Market
|
